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This study evaluates the accuracy of liquid chromatography-mass spectrometry (LC-MS) andmatrix-assisted laser desorption
ionization-time of flight mass spectrometry (MALDI-TOF) for detecting carbapenem hydrolytic activity among SPM-1-, GIM-1-,
and GES-5-producing Pseudomonas aeruginosa isolates and OXA-143-, IMP-10-, and OXA-58-producing Acinetobacter bau-
mannii isolates. Class A and B carbapenemase activities were rapidly detected byMALDI-TOF in a 2-h assay. However, an ex-
tended incubation time was necessary for detection of carbapenem-hydrolyzing class D -lactamase (CHDL) activity in Acineto-
bacter spp.
Over the last two decades, the therapeutic options to treat in-fections caused by Gram-negative rods have been narrowed
by bacterial acquisition of carbapenemase-encoding genes (1).
The rapid detection of clinically significant carbapenemases is im-
portant for establishing adequate therapy and controlling their
spread. Recently, the detection of class A or B carbapenemase
activity has been accomplished bymatrix-assisted laser desorption
ionization–time of flight mass spectrometry (MALDI-TOF MS)
(2, 3). Although MALDI-TOF MS seems to be a promising tool,
there is a lack of evidence showing its usefulness in testing a
broader range of carbapenemases. To date, the published studies
have mainly focused on KPC-2- and NDM-1-producing Entero-
bacteriaceae, IMP-1-, VIM-1-, and VIM-2-producing Pseudomo-
nas aeruginosa, andOXA-23- andOXA-24-producingAcinetobac-
ter baumannii isolates (2–4). In the current study,we evaluated the
performance of theMALDI-TOFMS assay in detecting carbapen-
emase activity of GES-5-, GIM-1-, or SPM-1-producing P. aerugi-
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TABLE 1 Characterization of the 73 clinical isolates and performance of carbapenemase detection by different methodologiesa
Bacterial species
Enzyme(s)
produced
No. of
isolates
MIC range (g/ml)
% of isolates detected as carbapenemase producers (no. of positive isolates/total
no. of isolates)
ETP IMP MEM MHT
IMP
hydrolysis
MALDI-TOF LC-MS
2 h 4 h 2 h 4 h
Acinetobacter baumannii 41
Oxa-23 16 16–256 4–64 0.5–128 56 (9/16) 100 (16/16) 19 (3/16) 100 (16/16) 19 (3/16) 100 (16/16)
Oxa-23, Oxa-143 4 256–256 32–256 32–256 100 (4/4) 100 (4/4) 75 (3/4) 100 (4/4) 75 (3/4) 100 (4/4)
Oxa-24, Oxa-143 1 256 128 256 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1)
Oxa-25 1 256 128 256 100 (1/1) 100 (1/1) 0 (0/1) 100 (1/1) 0 (0/1) 100 (1/1)
Oxa-26 1 256 128 256 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1)
Oxa-58 3 64–128 16 8–32 0 (0/3) 100 (3/3) 0 (0/3) 100 (3/3) 0 (0/3) 100 (3/3)
Oxa-23, Oxa-
143, IMP-1
1 256 128 256 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1)
IMP-10 3 8–128 0.5–32 4–64 67 (2/3) 100 (3/3) 100 (3/3) 100 (3/3) 100 (3/3) 100 (3/3)
Negative control 11 2–8 0.06–0.25 0.25–1 0 (0/11) 0 (0/11) 0 (0/11) 0 (0/11) 0 (0/11) 0 (0/11)
Klebsiella pneumoniae 6
KPC-2 1 32 8 8 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1)
NDM-1 1 128 64 32 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1)
ESBL/OmpK36 4b 0.25 0.25–2 0.06–16 0 (0/4) 0 (0/4) 0 (0/4) 0 (0/4) 0 (0/4) 0 (0/4)
Pseudomonas aeruginosa 26
GES-5 1 256 16 256 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1)
GES-1 1 64 1 4 0 (0/1) 0 (0/1) 0 (0/1) 0 (0/1) 0 (0/1) 0 (0/1)
SPM-1 11 256 128–256 64–256 64 (7/11) 100 (11/11) 100 (11/11) 100 (11/11) 100 (11/11) 100 (11/11)
IMP-1 1 256 32 256 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1) 100 (1/1)
VIM-1 2 256-256 256 256 0 (0/2) 100 (2/2) 100 (2/2) 100 (2/2) 100 (2/2) 100 (2/2)
GIM-1 4 256 128–256 256–256 100 (4/4) 100 (4/4) 100 (4/4) 100 (4/4) 100 (4/4) 100 (4/4)
Negative control 6 4–256 0.5–16 0.06–32 0 (0/6) 0 (0/6) 0 (0/6) 0 (0/6) 0 (0/6) 0 (0/6)
a ETP, ertapenem; IPM, imipenem; MEM, meropenem; MHT, modified Hodge test; MALDI-TOF, matrix-assisted laser desorption ionization-time of flight mass spectrometry;
LC-MS, liquid chromatography-mass spectrometry.
b Isolates previously characterized by Carvalhaes et al. (5).
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nosa and IMP-10-, OXA-58-, or OXA-143-producingA. bauman-
nii isolates which had not been tested previously. The detection of
carbapenemase by MALDI-TOF MS was compared to that of the
modified Hodge test (MHT) and hydrolysis assay. Additionally,
liquid chromatography-mass spectrometry (LC-MS) was used to
confirm the results of carbapenem hydrolysis obtained by
MALDI-TOF MS.
A total of 73 carbapenemase-producing and non-carbapen-
emase-producing bacterial clinical isolates were studied and mo-
lecularly characterized as shown in Table 1. Generally, no carbap-
enemase-producing isolates were susceptible to imipenem (IPM)
and meropenem (MEM), except for three A. baumannii isolates
(oneOXA-23 and two IMP-10 producers) that showed imipenem
and/or meropenem MICs of 4 g/ml by the agar dilution tech-
nique (5, 6). In our study, MHT using ertapenem (ETP) disks (10
g), following CLSI guidelines, detected 55%, 100%, and 68% of
carbapenem-hydrolyzing class D -lactamase (CHDL) and class
A and class B carbapenemases, respectively. No additional carbap-
enemase producers were identified by testing with meropenem
disks (7). Recently, MHT was reported to have poor sensitivity
FIG 1 (A) The hydrolysis of ETP mediated by -lactamases occurs in two steps: in the first step, the ETP intact molecule (475 g mol1) suffers a rupture on its
-lactam ring, resulting in a hydrolyzed ETPmolecule (493 gmol1). In the second step, the hydrolyzed ETPmolecule loses a carboxyl group (CO2), resulting
in ametabolite with amolecularmass of 450 gmol1 (hydrolyzed and decarboxylated ETPmolecule). (B) Analysis of ETP degradation byMALDI-TOFMS. (B1)
Results for a negative-control strain incubated with ETP solution which appears ionized with hydrogen ([ETP H]  475 g mol1) and its sodium adduct
([ETPNa] 497 g mol1). (B2) Results for a hydrolyzed and decarboxylated ETP after incubation with SPM-1-producing P. aeruginosa. Arrows represent
HCCA matrix peaks. (C) Analysis of ETP degradation by LC-MS. (C1) Results for a negative-control strain incubated with ETP which appears ionized with
hydrogen ([EPTH] 476 g mol1). (C2) Hydrolyzed and decarboxylated ETP after incubation with SPM-1-producing P. aeruginosa ([ETPH] 450
g mol1).
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and specificity for detecting class B and D carbapenemase activity
in carbapenem-resistant A. baumannii isolates (8). Indeterminate
and false-positive results by MHT were observed in our study for
non-carbapenemase-producingP. aeruginosa andKlebsiella pneu-
moniae ESBL/OmpK36 isolates, respectively, as was observed
previously (9, 10, 11). All carbapenemase isolates hydrolyzed imi-
penem according to a UV spectrometric assay using 100 mM
phosphate buffer (pH 7.0) (9).
The LC-MS and MALDI-TOF MS assays were performed by
incubating fresh bacterial inoculums from Mueller-Hinton agar
plates (Oxoid, Basingstoke,UnitedKingdom) in a buffer-adjusted
solution (20 mM Tris-HCl, pH 6.8) with or without serial dilu-
tions of ertapenem (0.12 to 0.5 g/ml; Merck Sharp & Dohme,
NJ) for periods of 2 and 4 h. This buffer solutionwas selected since
a NaCl solution could inhibit the CHDL activity. After centrifu-
gation, 1-l aliquots of each sample were overlaid with 1 l of
	-cyano-4-hydroxycinnamic acid matrix solution (HCCA;
Bruker Daltonics, Bremen, Germany) and spotted onto a stainless
steel MALDI target plate as recommended by the manufacturer.
The mass spectrum was obtained by using a Bruker Daltonics
Microflex LT instrument operating in linear, positive ion mode
and using the Flex Control 3.3 software with the following instru-
ment parameters: pulsed ion extraction delay, 30 ns; ion source
voltage one, 20 kV; ion source voltage two, 18.65 kV; and ion
source lens voltage, 7.00 kV. The mass spectrometer was cali-
brated using the HCCA matrix peaks ([MH]  189.17; [2
MH]  379.35) and bradykinin fragment 1-7 ([MH] 
757.40). For each sample, mass spectra were acquired by accumu-
lating 100 laser shots at 45% to 60% laser power in them/z range
of 200 to 600 Da. Carbapenem hydrolysis was considered positive
if the ertapenem intact-molecule mass peak (475m/z) and that of
its monosodium salt (497 m/z) disappeared completely (Fig. 1A
and B2) (2).
LC-MSwas performed in an LCMS-2020 instrument equipped
with an electrospray ionization probe (ESI-145; Shimadzu, Kyoto,
Japan). Aliquots of 15 l from each reaction tube were applied
directly into the instrument. The analytical LC-MS conditions
were as follows: an XR-ODS C18 column (2 m, 3.0 by 100 mm)
was eluted with solvent system A (water/trifluoroacetic
acid[TFA], 1:1,000) and B (acetonitrile/water/TFA 900:100:1) at a
flow rate of 1 ml/min and a 0-to-80% gradient for 10 min, moni-
tored by absorbance at 220 nm. The mass spectrum profile was
considered positive using the same interpretative criteria estab-
lished for the MALDI-TOF MS assay.
The performance of the MALDI-TOFMS, LC-MS and hydro-
lysis assays in detecting class A (KPC-2 andGES-5) and B (SPM-1,
IMP-1, IMP-10, VIM-1, GIM-1, andNDM-1) carbapenemase ac-
tivity was excellent for both 2- and 4-h incubation times (100%
sensitivity and 100% specificity). A similar result was observed by
Burckhardt and colleagues, who tested an ertapenem MALDI-
TOF MS assay to detect carbapenemase activity of NDM-1,
VIM-1, VIM-2, and KPC-2 enzymes in P. aeruginosa isolates and
Enterobacteriaceae (2). In our study, an extended incubation pe-
riod (4 h) was necessary to detect carbapenemase activity in 100%
of the CHDL-producing A. baumannii isolates, mainly due to
OXA-23-producing isolates (Table 1). Probably an extended in-
cubation period was necessary for detection of the carbapenemase
activity in CHDL-producing isolates because these enzymes usu-
ally show a low level of carbapenem hydrolysis due to poor turn-
over of these -lactams, as previously noticed by Queenan and
Bush (12). In addition, the expression of CHDL-encoding genes is
driven by an upstream-inserted insertion sequence, ISAba1 (13).
LC-MS confirmed all MALDI-TOF MS results. Recently, Kempf
and colleagues observed a similar detection rate (95% sensitivity)
in a collection of OXA-23- and/or OXA-24-producing A. bau-
mannii isolates by MALDI-TOF MS using imipenem and HCCA
as the substrate and matrix, respectively (4). In the present study,
imipenem was not selected for the MALDI-TOF MS because the
mass spectrum profile obtained did not show good resolution
with overlap of mass peaks, even when different matrices were
tested. It could be due to theMALDI-TOFMS system tested in our
study, the Microflex LT instrument, since Kempf and colleagues
tested the Ultraflex I mass spectrometer. However, the Microflex
LT instrument has been the apparatus mostly available in the Eu-
ropean clinical laboratories.
Although the hydrolysis assay yielded excellent results, this
method is laborious to implement in routine clinical laboratories.
To our knowledge, this is the first study to evaluate the perfor-
mance ofMALDI-TOFMS in detecting carbapenemase activity in
a collection of SPM-1-, GES-5-, and GIM-1-producing P. aerugi-
nosa isolates, as well as OXA-143-, IMP-10-, and OXA-58-pro-
ducing A. baumannii isolates. In addition, the MALDI-TOF MS
results were confirmed by using LC-MS. MALDI-TOF MS is a
rapid tool to detect class A and B carbapenemase activity, includ-
ing that of SPM-1-producing P. aeruginosa, in a 2-h assay. How-
ever, an extended incubation period of 4 h must be used for de-
tection of CHDL activity. MALDI-TOFMS has been shown to be
an easy, rapid, and cheap methodology for the detection of car-
bapenemase activity. It can yield results before those of antimicro-
bial susceptibility testing can be available and constitutes a very
attractive methodology, especially for clinical laboratories that
have already used this technique for bacterial identification.
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